Furthermore, treatment with a specific activator of TRPML1, ML1-SA1, decreases mitochondrial membrane potential through excessive activation of TRPML1 in liver cancer cells, resulting in mitochondrial damage and dysfunction (81). Here, MCOLN1 is linked to liver cancer.